Markets:

Overview

News

Currencies

International

Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

9.440 +0.130 (+1.40%)

Streaming Delayed Price Updated: 3:09 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings ↗

February 18, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO...

Via Benzinga

Recap: Prothena Corp Q4 Earnings ↗

February 17, 2022

Prothena Corp (NASDAQ:PRTA) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios ↗

February 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel...

Via Benzinga

Earnings Scheduled For February 17, 2022 ↗

February 17, 2022

Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.

Via Benzinga

Analyst Ratings For Prothena Corp ↗

November 19, 2021

Within the last quarter, Prothena Corp (NASDAQ:PRTA) has observed the follo...

Via Benzinga

Expert Ratings For Prothena Corp ↗

September 30, 2021

Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA

Via Benzinga

Expert Ratings For Prothena Corp ↗

September 27, 2021

Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA

Via Benzinga

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗

February 13, 2022

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...

Via Benzinga

Why Jim Cramer Prefers This Mining Stock Over Vale ↗

January 13, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said ChargePoint Holdings, Inc. (NYSE:

Via Benzinga

The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗

January 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...

Via Benzinga

Expert Ratings For Prothena Corp ↗

September 17, 2021

Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA

Via Benzinga

Expert Ratings For Prothena Corp ↗

September 14, 2021

Within the last quarter, Prothena Corp (NASDAQ:PRTA) has observed the foll...

Via Benzinga

4 Stocks Insiders Are Buying ↗

January 13, 2022

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...

Via Benzinga

50 Biggest Movers From Yesterday ↗

January 13, 2022

Gainers electroCore, Inc. (NASDAQ: ECOR) shares jumped 64% to settle at $0.88 on Wednesday after the company's gammaCore nVNS device received FDA Breakthrough Designation for...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 12, 2022

Gainers Biomerica (NASDAQ:BMRA) stock inc...

Via Benzinga

28 Stocks Moving In Wednesday's Mid-Day Session ↗

January 12, 2022

Gainers Immuron Limited (NASDAQ: IMRN) shares jumped 40.2% to $3.5887. Immuron received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing...

Via Benzinga

Mid-Morning Market Update: Markets Open Higher; US Inflation Rate Rises To 7% In December ↗

January 12, 2022

Following the market opening Wednesday, the Dow traded up 0.56% to 36,453.49 while the NASDAQ rose 0.79% to 15,273.08. The S&P also rose, gaining, 0.60% to 4,741.45. The U.S....

Via Benzinga

Best Stocks Of 2021: Meme Stocks, Biotechs Highlight Broad Sector Strength ↗

December 31, 2021

The list features stocks from diverse sectors as the economy recovers from the pandemic.

Via Investor's Business Daily

7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts ↗

December 07, 2021

These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months.

Via InvestorPlace

7 A-Rated Biotechs to Buy for the Long Run ↗

December 03, 2021

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

Via InvestorPlace

Prothena Corp: Q3 Earnings Insights ↗

November 04, 2021

Prothena Corp (NASDAQ:PRTA) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

7 A-Rated Healthcare Stocks to Buy for the Long Haul ↗

November 01, 2021

It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗

November 19, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Via Benzinga

What 8 Analyst Ratings Have To Say About Prothena Corp ↗

September 20, 2021

Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA

Via Benzinga

With Prothena Up Over 500% This Year, Is It Too Late to Get in? ↗

September 18, 2021

Promising drug candidates could lead to a best-in-class Alzheimer's treatment.

Via The Motley Fool

The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself ↗

September 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:...

Via Benzinga

Return on Capital Employed Insights for Prothena Corp ↗

September 02, 2021

According to Benzinga Pro, during Q2, Prothena Corp (NASDAQ:PRTA) earned $27.95 million, a 187.04% increase from the preceding quarter. Prothena Corp also posted a total of $60.07...

Via Benzinga

The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering ↗

September 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU...

Via Benzinga

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical ↗

August 31, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration ↗

August 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.